FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to maieutics, and can be used for treating placental insufficiency in pregnant women suffering from vaginal dysbiosis. For this purpose it is combined with complex drug-induced and laser therapy. During 6 days daily pregnant vaginal sanitation with 0.01 % miramystine for 5 minutes. Tablets of fluomizine are introduced at bedtime. Optimum dose of laser exposure is selected based on parameters of ultrasonic examination, doplerography examination and cardiotocography of foetus. In disturbed uterine-placental perfusion of 1a degree, delay of intrauterine growth retardation on 1 week, sum of Fisher indicators of 7 points daily percutaneous exposure on median cubital vein at wave length of 905 nm, frequency 1000 Hz, radiation power 50 W, for 2 minutes, therapeutic course is 5 procedures. In disturbed uterine-placental perfusion 1b degree, gestational delay of 2 weeks and sum of Fisher indicators of 6-7 points daily percutaneous exposure on ulnar vein with laser device at wave length of 905 nm, frequency 1,000 Hz, radiation power 50 W, for 5 minutes, daily therapeutic course is 7 procedures. In disturbed uterine-placental perfusion of 2 degree, delay of intrauterine growth retardation of 3 weeks, evaluation by Fischer of 6 points daily percutaneous exposure on anterior abdominal wall within projection of placenta wavelength 905 nm, frequency 1,000 Hz, power 65 W, for 6 minutes. Daily therapeutic course is 10 procedures.EFFECT: method provides higher clinical effectiveness, reduced length of treatment, reduced drug load on body of pregnant woman.1 cl, 3 tbl, 3 exИзобретение относится к медицине, а именно к акушерству, и может быть использовано для лечения плацентарной недостаточности у беременных с вагинальными дисбиозами. Для этого одновременно проводят комплексную медикаментозную и лазерную терапию. В течение 6 суток беременным ежедневно проводят санацию влагалища 0,01% раствором Мирамистина в течение 5 минут
